Since alectinib shows a better PFS and adverse event profile than crizotinib in Japanese patients with ALK-inhibitor-naïve ALK+ NSCLC [11], it has been approved for the treatment of recurrent or refractory ALK+ ALCL in Japan. Here, ALK is linked to anaplastic large cell lymphoma.